Hepion Pharmaceuticals Results Presentation Deck
October 2022, 34 slides
  1. Hepion Pharmaceuticals
  2. Related Decks
  3. Results Presentation Decks
i vei a novel drug candidate for nash fibrosis and creating a therapeutic ecosystem | Hepion Pharmaceuticals
forward looking statements | Hepion Pharmaceuticals
highlights anti fibrotic drug candidate cell injury | Hepion Pharmaceuticals
landscape of clinical drug development opportunity for collagen targeting therapeutics only approved drugs | Hepion Pharmaceuticals
collagen core to fibrotic diseases excessive collagen production universal to every fibrotic disease | Hepion Pharmaceuticals
fibrotic collagen production cyp participant in several stages of collagen synthesis and fibrotic scar formation | Hepion Pharmaceuticals
inhibits three primary hitting the right targets fibrosis inflammation and cell injury death anti fibrotic anti inflammatory | Hepion Pharmaceuticals
preclinical models consistent findings activity observed in every preclinical model | Hepion Pharmaceuticals
summary of programs pipeline within a product | Hepion Pharmaceuticals
fibrotic liver disease | Hepion Pharmaceuticals
the need and opportunity nash is driving a crisis nash a globally gee and | Hepion Pharmaceuticals
challenges to achieve development and commercial success a comprehensive approach to provide solutions need for commercial strategy | Hepion Pharmaceuticals
overview of phase studies completed | Hepion Pharmaceuticals
phase studies completed safe and well tolerated key findings | Hepion Pharmaceuticals
overview of phase a ambition nash trial completed | Hepion Pharmaceuticals
phase a ambition nash study safety tolerability and nash | Hepion Pharmaceuticals
phase a ambition nash study all primary met | Hepion Pharmaceuticals
proprietary artificial intelligence | Hepion Pharmaceuticals
proprietary state of the art artificial intelligence developing a panel for clinical development and commercialization | Hepion Pharmaceuticals
applied to the phase a program guiding future development | Hepion Pharmaceuticals
fibrosis associated gene network observed in phase a blood samples supports efficacy in day study expression related to coset ies so | Hepion Pharmaceuticals
phase ascend nash trial in progress | Hepion Pharmaceuticals
phase ascend nash biopsy trial | Hepion Pharmaceuticals
phase ascend nash | Hepion Pharmaceuticals
phase altitude nash trial in progress | Hepion Pharmaceuticals
phase altitude nash liver function trial | Hepion Pharmaceuticals
phase altitude nash liver function trial | Hepion Pharmaceuticals
phase a trial upcoming | Hepion Pharmaceuticals
phase a advanced carcinoma safety tolerability and efficacy nee a | Hepion Pharmaceuticals
| Hepion Pharmaceuticals
approach to developing an ecosystem creating a bundle to support success strategy | Hepion Pharmaceuticals
tackling fibrotic diseases currently marketed two value drivers a | Hepion Pharmaceuticals
experienced team | Hepion Pharmaceuticals
contact us a | Hepion Pharmaceuticals
See More
Hepion Pharmaceuticals
Results Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Liver
Inflammation
Clinical trial
Drug development
Related decks
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
Axcella Health
Results
September 2022
Arbutus Biopharma
Investor Presentation
March 2023
BenevolentAI
Investor Presentation
June 2022
Albireo Pharma
Results
October 2022
Arbutus Biopharma
Investor Presentation
August 2023
Arbutus Biopharma
Investor Presentation
May 2023
Certara
Investor Presentation
May 2022
NeuroBo Pharmaceuticals
Investor Presentation
December 2023
Axcella Health
Results
September 2022
Arbutus Biopharma
Investor Presentation
March 2023
BenevolentAI
Investor Presentation
June 2022
Albireo Pharma
Results
October 2022
Arbutus Biopharma
Investor Presentation
August 2023
Arbutus Biopharma
Investor Presentation
May 2023
Certara
Investor Presentation
May 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights